

IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1–8 (cancelled).

9 (currently amended). ~~Combination~~ A combination preparation ~~for treating depression,~~ comprising (a) rotigotine or a metabolite, prodrug or physiologically acceptable salt thereof, and (b) at least one [[a]] further active ingredient selected from the group consisting of antidepressants, antipsychotics, sedatives, anxiolytics [[or]] and anti-migraine agents.

10 (currently amended). ~~Method~~ A method for treating depression in a mammal, comprising ~~the administration of~~ administering a therapeutically effective quantity of rotigotine or a ~~rotigotine~~ metabolite, prodrug or physiologically acceptable salt thereof, to said mammal.

11 (new). The method of claim 10, wherein the mammal is human.

12 (new). The method of Claim 11, wherein the depression is an endogenous depression or an organic depression not associated with Parkinson's disease.

13 (new). The method of Claim 11, wherein the depression is a unipolar depression (major depression) or a depressive episode of a manic-depressive disorder.

14 (new). The method of Claim 11, wherein the depression is an organic depression which is independent of Parkinson's disease.

15 (new). The method of Claim 11, wherein the depression is a Parkinson's disease-associated depression.

16 (new). The method of Claim 15, wherein co-medication with another antidepressant is absent.

17 (new). The method of Claim 11, wherein the rotigotine or metabolite, prodrug or salt thereof is administered parenterally, transdermally or mucosally.

18 (new). The method of Claim 11, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in a dosage of 0.5 to 50 mg per day.

- 19 (new). The method of Claim 11, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in a dosage of 0.5 to 10 mg per day.
- 20 (new). The method of Claim 11, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in a dosage of 0.5 to 5 mg per day.
- 21 (new). The method of claim 11, wherein the rotigotine is administered as a prodrug thereof.
- 22 (new). The method of Claim 21, wherein the prodrug is an ester, carbamate, carbonate, ketal, acetate, phosphate, phosphonate, sulfate or sulfonate.
- 23 (new). The method of Claim 11, wherein the rotigotine is administered transdermally as rotigotine free base or hydrochloride salt.
- 24 (new). The method of Claim 23, wherein the rotigotine is formulated as an ointment, paste, spray, film, plaster or iontophoretic device for transdermal administration.
- 25 (new). The method of Claim 23, wherein the rotigotine is formulated as a plaster having the rotigotine in a matrix comprising an adhesive polymer.
- 26 (new). The method of Claim 23, wherein a substantially constant plasma level of rotigotine is established.
- 27 (new). The method of Claim 10, further comprising administering to the mammal at least one additional active ingredient selected from the group consisting of antidepressants, antipsychotics, sedatives, anxiolytics and anti-migraine agents.
- 28 (new). The combination preparation of Claim 9, wherein the at least one further active ingredient is an antidepressant selected from the group consisting of selective serotonin reuptake inhibitors, mixed serotonin and noradrenalin reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoamine oxidase inhibitors, alpha2 receptor modulators, serotonin receptor modulators, adenosine antagonists, sigma-opioid receptor ligands, NK antagonists, melatonin antagonists and modulators of the hypothalamus-hypophysis-adrenal axis.